Archive: March/April 2026

Is There an Optimal Sequential Order to Androgen Receptor Axis Therapeutics?

Abstract: The hormonal therapeutic landscape in prostate cancer has expanded greatly over the last few decades with the advent of abiraterone acetate and second-generation antiandrogens such […]

Highlights in Multiple Myeloma

From the 2025 American Society of Hematology Annual Meeting December 6-9, 2025 • Orlando, Florida Teclistamab/Daratumumab Combination Improves Survival in Relapsed/Refractory Myeloma Progression-free survival (PFS) and […]

New Drugs for Relapsed or Refractory Multiple Myeloma

H&O  What are the most recent drug approvals for relapsed or refractory myeloma? BD  We have seen an influx of immunotherapies for relapsed or refractory myeloma […]

The Sequencing of Covalent and Noncovalent BTK Inhibitors in CLL

H&O  What are the most important differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors? JW  The covalent BTK inhibitors that have US Food and […]

Optimal Treatment for Metastatic HER2+ Breast Cancer

H&O  How common is human epidermal growth factor receptor 2 (HER2) overexpression in metastatic breast cancer? ST  Approximately 15% to 20% of all breast cancers are […]

When Will Circulating Tumor DNA Be Ready for Prime Time in Lymphoma?

H&O  What are the potential uses of circulating tumor DNA (ctDNA) in lymphoma? MR  The most impactful potential uses of ctDNA would be to improve outcomes […]

The Role of LGR5 in Epithelial Cancer

H&O  What are the limitations of current treatments for epithelial cancer?  JYB  Epithelial cancer, which affects the cells that line the organs, includes colorectal cancer, head […]

Letter From the Editor: Living With Regret, as an Oncologist

Regret is something I rarely felt as a young man, but now that I’m older, I experience it more often than I’d like as an oncologist. […]

Back to Archive